Rapivab™ (peramivir) – Expanded indication
September 20, 2017, – BioCryst announced the FDA approval of Rapivab (peramivir) injection, for the treatment of acute uncomplicated influenza in patients ≥ 2 years age who have been symptomatic for no more than 2 days.
Download PDF
